InnoTherapy Inc
SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasi… Read more
InnoTherapy Inc (246960) - Net Assets
Latest net assets as of September 2025: ₩24.57 Billion KRW
Based on the latest financial reports, InnoTherapy Inc (246960) has net assets worth ₩24.57 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩75.35 Billion) and total liabilities (₩50.78 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩24.57 Billion |
| % of Total Assets | 32.61% |
| Annual Growth Rate | N/A |
| 5-Year Change | 19.89% |
| 10-Year Change | N/A |
| Growth Volatility | 75.58 |
InnoTherapy Inc - Net Assets Trend (2015–2024)
This chart illustrates how InnoTherapy Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for InnoTherapy Inc (2015–2024)
The table below shows the annual net assets of InnoTherapy Inc from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩15.52 Billion | -17.91% |
| 2023-12-31 | ₩18.90 Billion | +44.90% |
| 2022-12-31 | ₩13.05 Billion | +29.43% |
| 2021-12-31 | ₩10.08 Billion | -22.13% |
| 2020-12-31 | ₩12.94 Billion | -14.19% |
| 2019-12-31 | ₩15.08 Billion | +58.46% |
| 2018-12-31 | ₩9.52 Billion | +207.38% |
| 2017-12-31 | ₩3.10 Billion | -49.02% |
| 2016-12-31 | ₩6.07 Billion | +197.51% |
| 2015-12-31 | ₩-6.23 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to InnoTherapy Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3216936969000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩3.62 Billion | 23.32% |
| Other Components | ₩51.51 Billion | 331.98% |
| Total Equity | ₩15.52 Billion | 100.00% |
InnoTherapy Inc Competitors by Market Cap
The table below lists competitors of InnoTherapy Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Superbag Company Limited
PINK:SUPBF
|
$5.38 Million |
|
3R Games SA
WAR:3RG
|
$5.38 Million |
|
Cubex Tubings Limited
NSE:CUBEXTUB
|
$5.39 Million |
|
Prasidha Aneka Niaga Tbk
JK:PSDN
|
$5.39 Million |
|
Intouch Insight Ltd
OTCQX:INXSF
|
$5.38 Million |
|
Cosigo Resources Ltd.
V:CSG
|
$5.38 Million |
|
Altamin Ltd
AU:AZI
|
$5.38 Million |
|
Tifa Finance Tbk
JK:TIFA
|
$5.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in InnoTherapy Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 18,902,868,460 to 15,517,324,180, a change of -3,385,544,280 (-17.9%).
- Net loss of 3,730,136,090 reduced equity.
- Other factors increased equity by 344,591,810.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-3.73 Billion | -24.04% |
| Other Changes | ₩344.59 Million | +2.22% |
| Total Change | ₩- | -17.91% |
Book Value vs Market Value Analysis
This analysis compares InnoTherapy Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.83x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.50x to 3.83x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1363.72 | ₩2040.00 | x |
| 2017-12-31 | ₩695.20 | ₩2040.00 | x |
| 2018-12-31 | ₩2136.89 | ₩2040.00 | x |
| 2019-12-31 | ₩2990.03 | ₩2040.00 | x |
| 2020-12-31 | ₩2565.84 | ₩2040.00 | x |
| 2021-12-31 | ₩1998.11 | ₩2040.00 | x |
| 2022-12-31 | ₩2329.54 | ₩2040.00 | x |
| 2023-12-31 | ₩2612.04 | ₩2040.00 | x |
| 2024-12-31 | ₩532.63 | ₩2040.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently InnoTherapy Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.04%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -78.74%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.55x
- Recent ROE (-24.04%) is above the historical average (-33.34%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | -35369.61% | 0.00x | 0.00x | ₩-4.12 Billion |
| 2016 | -12.81% | -773.63% | 0.01x | 1.16x | ₩-1.39 Billion |
| 2017 | -97.27% | -1485.79% | 0.05x | 1.36x | ₩-3.32 Billion |
| 2018 | -27.05% | -502.60% | 0.05x | 1.17x | ₩-3.53 Billion |
| 2019 | -26.45% | -575.82% | 0.04x | 1.14x | ₩-5.50 Billion |
| 2020 | -23.55% | -511.16% | 0.03x | 1.34x | ₩-4.34 Billion |
| 2021 | -49.90% | -991.39% | 0.02x | 3.16x | ₩-6.04 Billion |
| 2022 | -45.78% | -1614.99% | 0.01x | 2.36x | ₩-7.28 Billion |
| 2023 | -26.59% | -380.17% | 0.04x | 1.60x | ₩-6.92 Billion |
| 2024 | -24.04% | -78.74% | 0.20x | 1.55x | ₩-5.28 Billion |
Industry Comparison
This section compares InnoTherapy Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $98,321,642,752
- Average return on equity (ROE) among peers: 7.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| InnoTherapy Inc (246960) | ₩24.57 Billion | 0.00% | 2.07x | $5.38 Million |
| Shinhung (004080) | $87.31 Billion | 3.50% | 0.52x | $10.80 Million |
| Osang Healthcare Co.,Ltd (036220) | $199.86 Billion | 20.34% | 0.25x | $37.44 Million |
| HansBiomed Corporation (042520) | $43.16 Billion | 11.38% | 0.21x | $246.58 Million |
| JVM Co. Ltd (054950) | $98.83 Billion | 10.23% | 0.72x | $117.37 Million |
| Huvitz Co. Ltd (065510) | $51.68 Billion | 16.97% | 0.32x | $43.64 Million |
| Vieworks Co. Ltd (100120) | $188.04 Billion | 17.80% | 0.28x | $101.54 Million |
| Corentec Co Ltd (104540) | $48.30 Billion | -3.04% | 0.46x | $40.80 Million |
| Hironic Co. Ltd (149980) | $40.72 Billion | 7.13% | 0.15x | $23.71 Million |
| Laseroptek Co., Ltd. (199550) | $-3.94 Billion | 0.00% | 0.00x | $21.68 Million |
| Humasis Co. Ltd (205470) | $229.26 Billion | -13.28% | 0.45x | $48.97 Million |